HER-2 overexpression/amplification in Barrett’s oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study
Corresponding Author
Elisa Rossi
2nd Department of Pathology, Spedali Civili, Brescia, Italy
Correspondence to: Dr. Elisa ROSSI, 2nd Department of Pathology, University of Brescia, Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25125 Brescia, Italy.Tel.: +39-030-3995830Fax: +39-030-3995053E-mail: [email protected]Search for more papers by this authorSalvatore Grisanti
Department of Medical Oncology, University of Brescia, Brescia, Italy
Search for more papers by this authorVincenzo Villanacci
2nd Department of Pathology, Spedali Civili, Brescia, Italy
Search for more papers by this authorDomenico Della Casa
Digestive Endoscopy, Department of General Surgery, University of Brescia, Brescia, Italy
Search for more papers by this authorPaolo Cengia
Digestive Endoscopy, Department of General Surgery, University of Brescia, Brescia, Italy
Search for more papers by this authorGuido Missale
Digestive Endoscopy, Department of General Surgery, University of Brescia, Brescia, Italy
Search for more papers by this authorLuigi Minelli
Digestive Endoscopy, Department of General Surgery, University of Brescia, Brescia, Italy
Search for more papers by this authorMichela Buglione
Department of Radiotherapy, University of Brescia, Brescia, Italy
Search for more papers by this authorRenzo Cestari
Digestive Endoscopy, Department of General Surgery, University of Brescia, Brescia, Italy
Search for more papers by this authorGabrio Bassotti
Gastroenterology & Hepatology Section, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy
Search for more papers by this authorCorresponding Author
Elisa Rossi
2nd Department of Pathology, Spedali Civili, Brescia, Italy
Correspondence to: Dr. Elisa ROSSI, 2nd Department of Pathology, University of Brescia, Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25125 Brescia, Italy.Tel.: +39-030-3995830Fax: +39-030-3995053E-mail: [email protected]Search for more papers by this authorSalvatore Grisanti
Department of Medical Oncology, University of Brescia, Brescia, Italy
Search for more papers by this authorVincenzo Villanacci
2nd Department of Pathology, Spedali Civili, Brescia, Italy
Search for more papers by this authorDomenico Della Casa
Digestive Endoscopy, Department of General Surgery, University of Brescia, Brescia, Italy
Search for more papers by this authorPaolo Cengia
Digestive Endoscopy, Department of General Surgery, University of Brescia, Brescia, Italy
Search for more papers by this authorGuido Missale
Digestive Endoscopy, Department of General Surgery, University of Brescia, Brescia, Italy
Search for more papers by this authorLuigi Minelli
Digestive Endoscopy, Department of General Surgery, University of Brescia, Brescia, Italy
Search for more papers by this authorMichela Buglione
Department of Radiotherapy, University of Brescia, Brescia, Italy
Search for more papers by this authorRenzo Cestari
Digestive Endoscopy, Department of General Surgery, University of Brescia, Brescia, Italy
Search for more papers by this authorGabrio Bassotti
Gastroenterology & Hepatology Section, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy
Search for more papers by this authorAbstract
Barrett’s oesophagus (BO) is the primary precursor lesion for oesophageal adenocarcinoma (ADC). The natural history of metaplasia-dysplasia-carcinoma sequence remains largely unknown. HER2/neu oncogene results overexpressed/amplified in preneoplastic lesions and in ADC of the oesophagus and it has been associated with poor prognosis. Our aim was to evaluate the role of HER2 overexpression/amplification in predicting the conversion from precursor lesions to ADC. We retrospectively evaluated by univariate analysis of single variables clinical records and histological specimens of 21 patients with a confirmed diagnosis of BO and/or oesophageal dysplasia. Clinical variables included age, gender, alcohol and smoking intake, presence of symptoms (pyrosis, disphagia) and endoscopic features (length). HER2 status was studied by immunohistochemistry and fluorescence in situ hybridization (FISH) on paraffin-embedded tissue. The end-points were the occurrence of progression and the time-to-progression (TTP) from the initial histologic lesion to the worst pathological pattern. Median age at diagnosis was 63 years (range 37–84). BO median length was 4.5 cm. Progression occurred in 11 of 21 patients and median TTP was 24 months. HER2 was overexpressed/amplified in 8 of 21 (38%) patients. HER2 overexpression/ amplification and the presence of dysplasia were statistically associated with progression (P= 0.038). This study provides evidence for a possible role of HER2 in the transition from dysplasia to ADC of the oesophagus. This fact could help in identifying patients at high risk of malignant transformation.
References
- 1 Paulson TG, Reid BJ. Focus on Barrett’s esophagus and esophageal adenocarcinoma. Cancer Cell. 2004; 6: 11–6.
- 2 DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol. 2006; 13: 12–30.
- 3 Parkin DM, Bray F, Ferlay Y, et al . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74–108.
- 4 Kelloff GJ, Lippman SM, Dannenberg AJ, et al . Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer. A plan to move forward. Clin Cancer Res. 2006; 12: 3661–97.
- 5 Reid BJ, Levine DS, Longton G, et al . Predictors of progression to cancer in barrett’s esophagus: baseline histology and flow cytometry to identify low- and high-risk patient subsets. Am J Gastroenterol. 2000; 95: 1669–76.
- 6 Buttar NS, Wang KK, Sebo TJ, et al . Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001; 120: 1630–9.
- 7 Conio M, Blanchi S, Lapertosa G, et al . Long-term endoscopic surveillance of patients with Barrett’s esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol. 2003; 98: 1931–9.
- 8 Oberg S, Wenner J, Johansson J, et al . Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg. 2005; 242: 49–54.
- 9 Chang EY, Morris CD, Seltman AK, et al . The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review. Ann Surg. 2007; 246: 11–21.
- 10 Pepe MS, Etzioni R, Feng Z, et al . Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001; 93: 1054–61.
- 11 Reid BJ, Prevo LJ, Galipeau PC, et al . Predictors of progression in Barrett’s esophagus. II: baseline 17p (p53) loss of heterozigosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001; 96: 2839–48.
- 12 Reid BJ, Blount PL, Rabinovitch PS. Biomarkers in Barrett’s esophagus. Gastrointest Endosc Clin N Am. 2003; 13: 369–97.
- 13 Schulmann K, Sterian A, Berki A, et al . Inactivation of p16, RUNX3 and HPP1 occurs early in Barrett’s-associated neoplastic progression and predicts progression risk. Oncogene. 2005; 24: 4138–48.
- 14 Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol. 1999; 9: 125–38.
- 15 Merrick DT, Kittelson J, Winterhalder R, et al . Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. Clin Cancer Res. 2006; 12: 2281–8.
- 16 Rossi E, Villanacci V, Bassotti G, et al . HER-2/neu in Barrett esophagus. A comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization. Diagn Mol Pathol. 2006; 15: 125–30.
- 17 Sampliner RE. Practice parameters Committee ACG: update guidelines for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2002; 97: 1888–95.
- 18 Cengia G, Missale G, Minelli L, et al . Screening for and surveillance of Barrett’s esophagus is clinically indicated. Dig Dis. 2007; 25: 197–202.
- 19 Conio M, Repici A, Cestari R, et al . Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett’s esophagus: an Italian experience. World J Gastroenterol. 2005; 11: 6650–5.
- 20 Cestari R, Villanacci V, Rossi E, et al . Fluorescence in situ hybridization to evaluate dysplasia in Barrett’s esophagus: a pilot study. Cancer Lett. 2007; 251: 278–87.
- 21 Lopes CV, Hela M, Pesenti C, et al . Circumferential endoscopic resection of Barrett’s esophagus with high-gradedysplasia or early adenocarcinoma. Surg Endosc. 2007; 21: 820–4.
- 22 Hamilton SR, Aaltonen LA. WHO pathology and genetics: tumors of digestive system. Lyon : IARC Press; 2000.
- 23 Villanacci V, Rossi E, Zambelli C, et al . COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett’s esophagus. Dig Liver Dis. 2007; 39: 305–11.
- 24 Villanacci V, Bellone G, Battaglia E, et al . Ski/SnoN expression in the sequence metaplasma-dysplasia-adenocarcinoma of Barrett’s esophagus. Hum Pathol. 2008; 39: 403–9.
- 25 Dako Hercep Test: Anti-Her2 IHC System for Immunoenzymatic Staining (package insert. Carpinteria , CA , USA ). Dako Corp, 2000.
- 26 Ishikawa T, Kobayashi M, Mai M, et al . Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol. 1997; 151: 761–8.
- 27 Walch A, Bink K, Gais P, et al . Evaluation of c-erbB-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett’s adenocarcinoma. Anal Cell Pathol. 2000; 20: 25–32.
- 28 Ellis IO, Dowsett M, Bartlett J, et al . Recommendations for HER2 testing in the UK. J Clin Pathol. 2000; 53: 890–2.
- 29 Ellis IO, Bartlett J, Dowsett M, et al . Best Practice No 176: updated recommendations for HER2 testing in the UK. J Clin Pathol. 2004; 57: 233–7.
- 30 Sharma P, Falk GW, Weston AP, et al . Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006; 4: 566–72.
- 31 Lim CH, Treanor D, Dixon MF, et al. Low-grade dysplasia in Barrett’s esophagus has a high risk of progression. Endoscopy. 2007; 39: 581–7.
- 32 Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist. 1998; 3: 237–52.
- 33 Mitchell MS, Press MF. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Semin Oncol. 1999; 26: 108–16.
- 34 Pauletti G, Dandekar S, Rong H, et al . Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000; 18: 3651–64.
- 35 Ross JS, Fletcher JA, Bloom KJ, et al . Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics. 2004; 3: 379–98.
- 36 Rabinovitch PS, Longton G, Blount PL, et al . Predictors of progression in Barrett’s esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001; 96: 3071–83.
- 37 Downs-Kelly E, Yoder BJ, Stoler M, et al . The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol. 2005; 29: 1221–7.
- 38 Weston AP, Sharma P, Mathur S, et al . Risk stratification of Barrett’s esophagus: updated prospective multivariate analysis. Am J Gastroenterol. 2004; 99: 1657–66.
- 39 Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998; 16: 413–28.
- 40 Slamon DJ, Leyland-Jones B, Shak S, et al . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783–92.
- 41 Berchuck A, Rodriguez G, Kamel A, et al . Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol. 1990; 76: 381–7.
- 42 Chang JL, Tsao YP, Liu DW, et al . The expression of type I growth factor receptors in the squamous neoplastic changes of uterine cervix. Gynecol Oncol. 1999; 73: 62–71.
- 43 Rygiel AM, van Baal JW, Milano F, et al . Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population. Cancer. 2007; 109: 1980–8.
- 44 Rygiel AM, Milano F, Ten Kate FJ, et al . Assessment of chromosomal gains as compared to DNA content changes is more useful to detect dysplasia in Barrett’s esophagus brush cytology specimens. Genes Chromosomes Cancer. 2008; 47: 396–404.
- 45 Villanacci V, Rossi E, Grisanti S, et al . Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett’s esophagus: a translational approach. Minerva Gastroenterol Dietol. 2008; 54: 347–53.